# Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

> **NCT03286114** · PHASE1 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03286114
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-21
- **Primary completion:** 2020-10-22
- **Final completion:** 2021-04-28
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Lack of patient population
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03286114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03286114, "Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03286114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*